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Abstract
DNA-based immunization has initiated a new era of vaccine research.
One of the main goals of gene vaccine development is the control of
the levels of expression in vivo for efficient immunization. Modifying
the vector to modulate expression or immunogenicity is of critical
importance for the improvement of DNA vaccines. The most fre-
quently used vectors for genetic immunization are plasmids. In this
article, we review some of the main elements relevant to their design
such as strong promoter/enhancer region, introns, genes encoding
antigens of interest from the pathogen (how to choose and modify
them), polyadenylation termination sequence, origin of replication for
plasmid production in Escherichia coli, antibiotic resistance gene as
selectable marker, convenient cloning sites, and the presence of
immunostimulatory sequences (ISS) that can be added to the plasmid
to enhance adjuvanticity and to activate the immune system. In this
review, the specific modifications that can increase overall expression
as well as the potential of DNA-based vaccination are also discussed.
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Introduction
Genetic immunization represents a novel
approach to vaccination. This technology
involves transfer of a gene encoding an anti-
genic protein cloned in expression vectors to
a host, leading to the induction of an immune
response. During the last two decades, dif-
ferent mammalian gene expression vectors
have been developed as well as new methods
for direct gene transfer. Several reviews on
the subject have been published (1-3). Direct
gene transfer may be undertaken using either
viral vectors or recombinant plasmid DNA.
Viral vectors have the disadvantages of be-
ing derived from pathogens like traditional
vaccines based on attenuated viruses, and
therefore they are of limited interest for the
purpose of immunization. In contrast, DNA
plasmids encoding antigen(s) are more fre-
quently used because they do not have the
inconvenience of classical vaccines: they are
safe, inexpensive, easy to produce, heat stable
and amenable to genetic manipulation. In
this review, we will deal with some of the
main elements relevant to the design of vec-
tors used for genetic vaccination. These vec-
tors are Escherichia coli-derived plasmids
capable of expressing foreign genes in eu-
karyotic cells. Conceptually, their struc-
ture can be divided into two distinct units: i)
a transcription complex unit that drives anti-
gen synthesis and that contains a promoter/
enhancer region, introns with functional splic-
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ing donor and acceptor sites, sequences en-
coding an antigenic protein, and signals re-
quired for efficient polyadenylation of the
transcript. ii) Prokaryotic elements such as
replication origin, multiple cloning sites and
a selectable marker to facilitate the construc-
tion, propagation and amplification of re-
combinant vectors in bacteria. This plasmid
backbone can also carry immunostimulatory
sequences (ISS) with adjuvant activity (Fig-
ure 1).
Basic structure of plasmid DNA
vaccines
The transcription complex unit
Enhancer/promoter regions. Almost all
commercial mammalian expression plasmids
carry the immediate early promoter/enhancer
from pathogenic viruses. Although these pro-
moter elements are from pathogenic viruses,
they have become very useful for gene
therapy and genetic immunization thanks to
their high transcription initiation ability in
most mammalian tissues (4). The most com-
monly used promoter is the one from human
cytomegalovirus (hCMV) which induces
strong and constitutive expression in a vari-
ety of cell types (5-7). The use of alternative
promoter/enhancer elements has been dis-
cussed, including Rous sarcoma virus (RSV),
simian virus 40 (SV40), murine leukemia
virus (SL3-3), mouse mammary tumor virus
(MMTV) promoter, and HIV long terminal
repeat (LTR) promoter (8-10). Among them,
the hCMV promoter gave the highest levels
of expression of the reported genes tested
and/or induced the strongest immune re-
sponses (11-13).
Another type of promoters, i.e., mamma-
lian promoters, have also been used. These
promoter elements are particularly interest-
ing for vaccine development since they may
be more desirable than DNA sequence from
pathogenic or tumor-causing viruses for ap-
plications involving humans or animals.
Gurunathan et al. (14) reported that the bo-
vine promoter/enhancer from the major his-
tocompatibility complex class I (MHC I)
gene gave significantly better protection than
that obtained with hCMV-derived plasmids.
Other mammalian promoters were tested,
including those from the beta-actin, muscle-
specific heavy chain of myosin and muscle
creatine kinase genes (mck) (7,15,16).
Discrete functional entities such as the
exogenous enhancer elements of aB crystal-
line gene (cryB) or mck can be incorporated
upstream in relation to the enhancer/pro-
moter region. Hartikka et al. (17) and Dai et
al. (18) reported that these entities prolong
and increase expression by the CMV promo-
tor/enhancer. In fact, the main function of
these elements is to control the gene initia-
tion transcription rate. In spite of the exist-
ence of various gene delivery systems, the
main question to be addressed is if the initia-
tion of the transferred gene transcription is
efficient and how long it lasts. The modula-
tion of this initiation rate can be essential to
obtain a positive genetic immunization ef-
fect.
It is sometimes advisable to introduce an
inducible promoter to control in vivo expres-
sion. This was done by Dhawan et al. (19)
and Liang et al. (20) who modified plasmids
to make tetracycline (Tc)-dependent tran-
scriptions. When tetracycline is administered
to transfected mice it can act in a repressive
or activating way depending on the position
of the tetracycline-operator (tetO) control
sequence within these Tc-controlled plas-
mids. The inducible systems have the advan-
tage of overcoming potential immunological
CMV enhancer/promoterISS
ampR
ISS
ISS
ColE1 poly (A)
Gene from pathogen
Figure 1 - Plasmid DNA pattern
for genetic immunization. i) The
transcription complex unit com-
prises promotor, intron, antigen
DNA and poly-adenylation (A)
addition sequence, which to-
gether drive protein synthesis.
ii) The elements of the plasmid
backbone unit such as prokary-
otic origin of replication (ColE1)
and a selectable marker (ampi-
cillin resistance gene; ampR).
This plasmid backbone also de-
livers adjuvant and mitogenic
activity via immunostimulatory
sequences (ISS).
pCMV +cDNA
7200 bp
Intron
149
Braz J Med Biol Res 32(2) 1999
Anatomy of plasmid vectors used in genetic immunization
tolerance that may exist in genetic immuni-
zation.
Introns. Intervening sequences (or in-
trons) have a beneficial effect on antigen
expression. This can be attributed to an en-
hanced rate of RNA polyadenylation and/or
nuclear transport linked to RNA splicing
(21), but can also indicate the presence of
transcriptional enhancers within the introns
(22).
Most expression vectors for gene vacci-
nation also include intron A from hCMV.
Indeed, some studies have revealed that ex-
pression and stimulation of an immune re-
sponse were enhanced by the addition of an
intron sequence upstream of the coding re-
gion (9,23). This location prevents the utili-
zation of possible cryptic 5’ donor splicing
sites within DNA sequences (21). These cryp-
tic sites hamper expression due to aberrant
splicing.
Chimeric introns can also be constructed
with sequences of the donor and acceptor
sites of different genes, and the branchpoint
site can be optimized to match the consensus
sequence leading to an increased expression
level (24).
Brinster et al. (25) showed that introns
improved transcriptional efficiency 10- to
100-fold in transgenic mice but they ob-
served little effect on gene expression when
compared to cells transfected in culture.
Various interpretations are possible but the
most plausible explanation is that introns
contain DNA sequences that are recognized
at some stage during development but are
not required after transfection, in established
cell lines. In conclusion, the studies that
examine the role of introns in expression
plasmid vectors show that the increase in in
vivo expression depends not only on the
presence or absence of introns, but also on
the position of introns within the transcrip-
tion unit.
Polyadenylation signal. Polyadenylation
has been shown to enhance RNA stability
and translation (26) which in turn vary ac-
cording to the different transcriptional gene
terminators. Moreover, as the rate of tran-
scriptional initiation is increased by the use
of strong promoter/enhancer, the process of
transcriptional termination may become rate-
limiting (18). Although transcriptional ter-
minators are not widely recognized as gene
regulatory elements, Hartikka et al. (17)
showed that modifications in transcriptional
terminator sequences such as their replace-
ment by other types of terminator sequences
or the construction of chimeric termination
sequences with more efficient polyadenyla-
tion signal or the lack of 3’ untranslated
region (UTR) sequences led to increases in
expression which can reflect the differences
in transcriptional termination efficiency.
Polyadenylation termination sequences
carried by DNA vaccine constructs usually
derive from bovine growth hormone (BGH),
as in pcDNA3 (Invitrogen, San Diego, CA,
USA), and VR1012 (Vical Co., San Diego,
CA, USA). Other vectors such as pcDNAI
(Invitrogen) and nkCMVintBL (Vical) have
late SV40-derived sequence terminators. The
late SV40 polyadenylation signal is very
efficient and increases the steady-state level
of RNA approximately 5-fold more than the
early SV40 polyadenylation signal (27).
These are located just downstream of the
multiple cloning sites. This location facili-
tates efficient processing of cloned genes
which may not have an efficient polyadeny-
lation signal.
Sequences encoding an antigenic pro-
tein. Recombinant DNA technology has en-
abled the construction of chimeric genes
with an optimized structure for genetic im-
munization. To be optimized, synthetic genes
require elimination of large hairpin struc-
tures in the 5’-end UTR mRNAs. It has been
shown that these structures reduce the level
of in vitro and in vivo translation in higher
eukaryotes (28,29). To initiate translation,
an ATG must be present in the inserted gene.
This ATG must also be the first one in the 5’
region and in the translational start site. Out-
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of-frame ATGs can reduce the rate of gene
translation (29). Kozak (29) has proposed a
consensus sequence for vertebrate mRNAs
located around the start site (-9 GCCGCCA/
GCCAUGG+4). She also pointed out that an
efficient translation is obtained in the -3
position containing a purine base. In the
absence of a purine base, the efficiency of
translation can be maintained with a guanine
at the +4 position. Genes of prokaryotic
organisms and some eukaryotic genes do not
have this consensus sequence. Its insertion
into the 5’-region of these genes might in-
crease the expression level.
In contrast to prokaryotic sequences, limi-
tations of size and availability often dictate
that the eukaryotic sequences to be expressed
be obtained in the form of cDNA. To con-
struct a synthetic gene it may be necessary to
leave some introns in their place and to
excise them during processing of the pri-
mary transcript. The presence of introns dur-
ing processing can sometimes increase the
levels of cytoplasmic messenger RNA (30).
The effects of manipulating the encoded
sequences by addition or deletion of secre-
tory control signals have also been evalu-
ated, and surprisingly they either had no
effect or reduced the immune response
(23,31). However, Hoffman et al. (32) re-
ported that in-frame gene fusions with the
sequence encoding the leader peptide of hu-
man tissue plasminogen activator protein
(tPA) enhance their expression.
In order to enhance the immune response
to a DNA vaccine, Boyle et al. (33) directed
the antigen to sites of immune-response in-
duction by vaccination with DNA encoding
antigen-ligand fusion proteins. These two
ligands bind to receptors that are present on
endothelial venule cells of lymph nodes or
on antigen-presenting cells. They showed
that both the humoral and cellular immune
responses to a model DNA vaccine were
enhanced using either antigen-targeting strat-
egy. The construction of optimized synthetic
genes combined with regulatory elements
produces a transcription unit capable of mod-
ulating genetic expression. The exact modu-
lation of the expression level elicits the de-
sirable immune responses.
Discovery of new antigenic proteins.
Genetic immunization offers an excellent
opportunity to quickly discover new anti-
gens and to handle the antigenicity of the
protein at the sequence level with the advan-
tage of not requiring protein production and
purification. Since it is easy and rapid to
clone and modify genes in plasmid expres-
sion vectors, many new constructs can be
produced and tested in a short period of time
such as entire expression libraries which can
be cloned and injected in a shot-gun fashion
to identify immunoprotective epitopes. A
very interesting application of DNA vacci-
nation has been developed to identify new
protective antigens. This strategy (termed
expression library immunization; ELI) is
based on immunization with an expression
library constructed with the genomic DNA
of the pathogen. It was initially developed by
Barry et al. (34) who demonstrated that im-
munization with partial expression libraries
made from genomic DNA of Mycoplasma
pulmonis protects mice challenged with the
pathogen. Similarly, Alberti et al. (35) in-
jected mice with an expression genomic li-
brary of Trypanosoma cruzi. Although the
protection was not assayed, it was possible
to detect expression of T. cruzi antigens in
the muscle and the specific IgG antibodies
produced.
The identification of antigens, their com-
binations and forms is the most effective
way to raise protective responses and is one
of the most important research areas for
DNA-based immunizations.
Plasmid backbone unit
Multiple cloning region, replication ori-
gin and prokaryotic selectable marker. The
backbone of plasmid DNA vectors carries a
multiple cloning site (MCS) that can be con-
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sidered to be additional elements of the tran-
scription unit. This MCS is especially de-
signed to avoid formation of hairpin struc-
tures in the 5’ end of the transcribed RNA
since hairpin structures can interfere with
translation.
The replication origin normally used in
expression plasmids is the origin of the
multicopy plasmid, ColE1. It is the best char-
acterized copy number and incompatibility
system and allows the maintenance at steady
level of more than 20 copies per E. coli cell,
resulting in a high DNA plasmid yield, im-
portant in gene vaccine production. The pres-
ervation of a high number of copies depends
on the mechanisms which initiate replica-
tion and is controlled by the ColE1 origin
(36). DNA vectors can also contain a viral
origin of replication. In this regard, SV40
(nkCMVintBL, Vical Co.) and polyoma
(pcDNAI, Invitrogen) have been used. Ap-
parently, the inclusion or deletion of such
sequences does not affect the expression
levels of the foreign peptides (37). These
findings, together with the necessity of satis-
fying concerns related to their potential clini-
cal use, indicate that replication sequences
of viral origin should be deleted from DNA
vectors.
Selectable markers provide a means to
select for growth only in those cells which
contain a vector. Such markers are of two
types: drug resistant and auxotrophic. Drug
resistant markers enable cells to detoxify an
exogenously added drug that would other-
wise kill the cell. Auxotrophic markers al-
low cells to synthesize an essential compo-
nent (usually an amino acid) in a medium
which lacks that component. A widespread
prokaryotic selectable marker is the beta-
lactamase ampicillin resistance gene (ampR)
which confers resistance to penicillin-based
antibiotics. Penicillin can induce anaphylac-
tic shock in sensitized individuals. Trace
amounts of this antibiotic may be present as
plasmid DNA contaminants. Replacing the
beta-lactamase gene with another antibiotic
cassette is possible but does not ease public
concern over its potential clinical use. The
use of auxotrophic markers can also be pos-
sible but there is a high contamination risk
with the essential component that is not nec-
essarily recommended for the immunized
host. It should be remembered that applica-
tion of direct gene transfer for genetic immu-
nization requires the availability of plasmid
DNA that is free of all contaminants, partic-
ularly toxic or immunogenic substances. This
contamination problem can be solved if a
purification technology combined with se-
lected E. coli strains and growth optimiza-
tion is used for each plasmid construction
(38).
Sequences as immunostimulatory ele-
ments. It has been shown that certain DNA
sequences can induce cytokine secretion and
lymphocyte activation (39). Certain CpG
motifs in bacterial DNA are particularly
stimulatory, whereas similar sequences from
other species are not. These observations
suggest that manipulation of DNA vaccines
to contain or to avoid these sequences may
affect the immunogenicity of the antigens
expressed by the vector. In this regard, Sato
et al. (40) found that CMV-based vectors
containing a bacterial ampR produced a stron-
ger immune response than a similar expres-
sion vector containing the kanamycin resis-
tance gene (kanR). In vitro transfection ex-
periments revealed that the ability to stimu-
late the immune response was not due to the
different amounts of antigen expressed by
the DNA constructs. The ampR gene con-
tains two copies of the ISS (palindromic
CpG hexamer 5’ AACGTT 3’), whereas no
ISS was identified within the kanR gene.
Klinman et al. (41) demonstrated that the
elimination of CpG motifs from the plasmid
backbone of DNA vaccines reduced vaccine
immunogenicity, and that this effect could
be reversed by co-administering exogenous
CpG-containing DNA. However, the magni-
tude of the immune response induced by
exogenous CpG oligonucleotides never
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equaled the effect of incorporating these
motifs into the plasmid backbone. These
findings indicate that the backbone of the
DNA vaccine delivers adjuvant and mito-
genic activity via ISS, suggesting that the
composition of the DNA vector may be an
important consideration in designing a DNA
vaccine.
The presence of CpG motifs in DNA
vaccines induces B-cell proliferation, im-
munoglobulin production and cytokine se-
cretion, and promotes the generation of a
strong immune response. These beneficial
properties of CpG-based adjuvants make
them excellent components of the vectors
used in DNA vaccines. Optimizing the num-
ber and the exact sequences of ISS can greatly
enhance the potency of DNA-based vaccina-
tion.
Concluding remarks
The structure and organization of the
elements influencing expression of DNA-
based immunization vectors show a great
deal of modularity. It is therefore possible to
obtain plasmids with uncommon, although
efficient combinations of promoter, enhancer,
introns, gene from a pathogen and signal of
polyadenylation to undertake specific tasks
in the genetic immunization protocol. The
adjuvanticity of CpG motifs turns them into
important elements to be included in the
plasmid backbone.
The molecular biological tools required
to test various regulatory modules, to clone
ISS, to remove unwanted or safetywise un-
acceptable sequences, to identify and modify
immunoprotective epitopes, are already avail-
able. In addition, obtaining high-level gene
expression is not a difficult task. However,
there is some controversy over the role of
high gene expression levels in genetic im-
munization. The key to the problem depends
on the antigen used as well as the type of
immune response expected, i.e., cellular,
humoral, or both. The exact modulation of
the expression level is necessary for each
newly tested antigen to elicit the desired
immune responses without modifying or shut-
ting down host cell function and causing
negative effects similar to those of tradi-
tional vaccines.
Now that many important vector elements
have been identified, efforts must be con-
centrated on testing their different combina-
tions and evaluating their immunogenic po-
tential. The study of potential biosafety risks
of DNA vaccines such as chromosomal inte-
gration and the induction of immunogical
tolerance must be also undertaken.
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